The largest community of pharma leaders

Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors

BOSTON–()–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced that it has consummated a private investment from Polaris Partners, a leading healthcare investment firm with a long history of partnering with entrepreneurs in biotechnology. Polaris Partners joins existing investor Takeda Pharmaceuticals. As part of the investment, Amy W. Schulman, a managing partner at Polaris Partners, will join the Cardurion Board of Directors.

“We are honored to have Polaris Partners, with its long history of leadership in biotechnology investing and company building, partner with us as we pursue novel drugs to treat cardiovascular diseases, and we are especially pleased to have Amy Schulman of Polaris bring her deep strategic and leadership experience to our board,” said Dr. Michael E. Mendelsohn, founder and chairman of Cardurion Pharmaceuticals. “Cardurion is dedicated to advancing novel mechanisms to create new treatments for cardiovascular diseases, which remain the greatest cause of morbidity and mortality in our society. Our lead clinical program studying CRD-733, a novel phosphodiesterase-9 enzyme (PDE9) inhibitor, is in development for the treatment of heart failure, which remains a major cause of death in our society. Our two discovery programs focus on unique molecular targets for other cardiovascular diseases, including both rare and more common arrhythmia disorders.”

Amy W. Schulman, a managing partner at Polaris Partners who will be joining Cardurion’s board, noted that cardiovascular disease affects millions of people in the United States alone. “This area of clear critical need, coupled with Michael’s deep expertise in the field, were important factors in Polaris’ decision to invest. Cardurion’s robust pipeline programs, led by a PDE9 inhibitor already in the clinic for the treatment of both forms of heart failure, are also factors underscoring Polaris’ enthusiasm for this platform.”

The securities issued have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful.

About Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Founded by physician-scientist Michael E. Mendelsohn, M.D., with extensive experience in cardiovascular science, medicine and drug development, Cardurion Pharmaceuticals is pursuing unique drug discovery and development programs targeting major unmet needs in cardiovascular medicine. Cardurion Pharmaceuticals has facilities in Boston, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at

About Polaris Partners

Polaris Partners has a 20-plus year history of partnering with repeat entrepreneurs and world-class innovators who are improving the way we live and work. The multibillion-dollar firm manages specialty and diversified funds in healthcare and technology with investments across all stages. Polaris has offices in Boston and San Francisco. Learn more at


Recent Articles

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene...

Global Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)-- #NeurofibromatosisTreatment--The Asia Pacific is expected to witness significant growth...

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food...

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today initiatives to bring attention to...

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.